MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Sarcomatoid

Less common than epithelioid mesothelioma, only 7% to 20% of mesothelioma are sarcomatoid. Often called the “wild” type because of it’s unpredictable nature.

The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-Based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Human Pathology 2017 August 4 [Epub ahead of print] [Link] Marchevsky AM, et. al. Abstract Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype […]

Comments Off on The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-Based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Archives of pathology and laboratory medicine 2017 July [Epub ahead of print] [Link] Husain AN et.al. Abstract CONTEXT: – Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: – To provide updated, practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: – Pathologists involved in the International Mesothelioma Interest […]

Comments Off on Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.

International Journal of Surgical Pathology 2017 June [Epub ahead of print] [Link] Takeda M, Kasai T, Hatakeyama K, Nakai T, Itami H, Uchiyama T, IIzuka N, Maruyama H, Ohbayashi Abstract BACKGROUND: Abnormality of genes including 9p21 is known in malignant mesothelioma and we have examined the frequency of gene deletion and amplification using the fluorescence […]

Comments Off on Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.

JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Current Cancer Drug Targets 2017 June 23 [Epub ahead of print] [Link] Zanellato I, Colangelo D, Osella D Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated tumor with poor prognosis and few therapeutic options. JQ1, a selective antagonist of BRD4, modulates transcription of oncogenes, including MPM chemoresistance-associated c-Myc and Fra-1. We investigated if JQ1 could […]

Comments Off on JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung

American Journal of Surgical Pathology 2017 June [Epub ahead of print] [Link] Berg KB, Churg A Abstract The separation of sarcomatoid and desmoplastic malignant mesotheliomas from sarcomatoid carcinomas of the lung metastatic to the pleura may be difficult, since both types of tumor can be morphologically similar and are frequently positive only for pan-keratin. GATA […]

Comments Off on GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Oncotarget 2017 May 11 [Epub ahead of print] [Link] Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, Conte PF, Ciminale V, Pasello G Abstract Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), suggesting that it may […]

Comments Off on Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.

British Journal of Cancer 2017 March 14 [Epub 2017 February 14] [Link] Muruganandan S, Alfonso H, Franklin P, Shilkin K, Segal A, Olsen N, Reid A, de Klerk N, Musk AB, Brims F Abstract BACKGROUND: Survival with the epithelioid subtype of malignant mesothelioma (MM) is longer than the biphasic or sarcomatoid subtypes. There is concern […]

Comments Off on Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Journal of Clinical Oncology 2017 April [Epub ahead of print] [Link] Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW Abstract Purpose Pegylated arginine deiminase (ADI-PEG […]

Comments Off on Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma

The Annals of Thoracic Surgery 2017 March [Epub 2016 October] [Link] Vigneswaran WT, Kircheva DY, Ananthanarayanan V, Watson S, Arif Q, Celauro AD, Kindler HL, Husain AN Abstract BACKGROUND: Macroscopic complete surgical resection with adjuvant chemotherapy can provide a survival advantage in patients with malignant pleural mesothelioma (MPM). Patients with nonepithelioid histology are largely excluded […]

Comments Off on Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma

International Journal of Oncology 2017 February 9 [Epub ahead of print] [Link] Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O’Byrne KJ, Cuffe S, Finn SP, Gray SG Abstract Malignant pleural mesothelioma (MPM) is a rare aggressive cancer of the pleura primarily associated with prior exposure to asbestos. The […]

Comments Off on Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma